Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels -

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
Information type: Randomised controlled trials
Source: JAMA Cardiology
Specialities: Cardiovascular system disorders
Summary
Prespecified analysis of phase 2 RCT (n=501) noted potent and durable lowering of LDL-C with a twice-a-year dosing regimen (day 1 and day 90) of inclisiran, an investigational CSK9 synthesis inhibitor (LDL-C decreased over 1 year by 29.9% to 46.4% in a dose-dependent manner)
UKMi comment
Inclisiran is under investigation in phase III clinical trials in the EU for hypercholesterolaemia despite maximum tolerated doses of LDL-C lowering therapies.
Related links: